AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32928030 — intervention group
Group type: COMPARATOR
Intervention: X‐ray location (control group)
Number of subjects: 158
Study 34254214 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 512
Study 34254214 — intervention group
Group type: COMPARATOR
Intervention: Prevailing health education
Number of subjects: 512
Study 33615528 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-based radiomic features for tumor stage prediction
Number of subjects: 157
Study 33615528 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-based radiomic features for pathological grade prediction
Number of subjects: 157
Study 32812137 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsterile irrigation
Number of subjects: 118
Study 32812137 — intervention group
Group type: COMPARATOR
Intervention: Sterile irrigation
Number of subjects: 118
Study 33212267 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) with low-power laser, 660 nm, 40 mW, 120 J/cm2, 4.8 J, 120 s per point and methylene blue (0.005 %) as photosensitizer
Number of subjects: 25
Study 33212267 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Acyclovir (AC) 5%
Number of subjects: 25
Study 33212267 — intervention group
Group type: EXPERIMENTAL
Intervention: PDT + AC
Number of subjects: 25
Study 33212267 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 25
Study 32423618 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical corticosteroids
Number of subjects: 80
Study 32423618 — intervention group
Group type: EXPERIMENTAL
Intervention: Elimination diets
Number of subjects: 80
Study 32423618 — intervention group
Group type: COMPARATOR
Intervention: Sensitisation to fruits
Number of subjects: 80
Study 32423618 — intervention group
Group type: COMPARATOR
Intervention: Sensitisation to grains
Number of subjects: 80
Study 32423618 — intervention group
Group type: COMPARATOR
Intervention: Impaction
Number of subjects: 80
Study 32423618 — intervention group
Group type: COMPARATOR
Intervention: Dysphagia
Number of subjects: 80
Study 32423618 — intervention group
Group type: COMPARATOR
Intervention: Abdominal pain
Number of subjects: 80
Study 32423618 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic findings - exudates
Number of subjects: 80
Study 32423618 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic findings - trachealisation
Number of subjects: 80
Study 32423618 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic findings - stenosis
Number of subjects: 80
Study 33788881 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 20
Study 33788881 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 20
Study 32826717 — intervention group
Group type: EXPERIMENTAL
Intervention: Ala-Gln at 12g/day
Number of subjects: 140
Study 32826717 — intervention group
Group type: EXPERIMENTAL
Intervention: Ala-Gln at 3g/day
Number of subjects: 140
Study 32826717 — intervention group
Group type: EXPERIMENTAL
Intervention: Ala-Gln at 6g/day
Number of subjects: 140
Study 32826717 — intervention group
Group type: EXPERIMENTAL
Intervention: Ala-Gln at 3g/day, 6g/day, and 12g/day
Number of subjects: 140
Study 32826717 — intervention group
Group type: EXPERIMENTAL
Intervention: Ala-Gln
Number of subjects: 140
Study 32826717 — intervention group
Group type: COMPARATOR
Intervention: Gly placebo at 12.5g/day
Number of subjects: 140
Study 33421649 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of HPV vaccine (Cervarix or Gardasil-9)
Number of subjects: 930
Study 33421649 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of HPV vaccine (Cervarix or Gardasil-9) given 6 months apart
Number of subjects: 930
Study 33421649 — intervention group
Group type: EXPERIMENTAL
Intervention: Three doses of HPV vaccine (Cervarix or Gardasil-9)
Number of subjects: 930
Study 32187166 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Oral Anticoagulants (DOACs), primarily Rivaroxaban and Apixaban
Number of subjects: 52
Study 32187166 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified (standard treatment with warfarin)
Number of subjects: 52
Study 36242636 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-ALA (20 mg/kg) administered orally or via a gastric tube prior to surgery
Number of subjects: 14
Study 34182577 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-administered oral stimulation (PIOMI)
Number of subjects: 39
Study 34182577 — intervention group
Group type: COMPARATOR
Intervention: Professional-administered oral stimulation (PIOMI)
Number of subjects: 39
Study 33903280 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intervention
Number of subjects: 28
Study 33903280 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose intervention
Number of subjects: 28
Study 33903280 — intervention group
Group type: EXPERIMENTAL
Intervention: Both doses
Number of subjects: 28
Study 32202965 — intervention group
Group type: EXPERIMENTAL
Intervention: Regenerative endodontic procedures (REP)
Number of subjects: 36
Study 32202965 — intervention group
Group type: COMPARATOR
Intervention: Conventional root canal treatment (ENDO)
Number of subjects: 36
Study 34229508 — intervention group
Group type: EXPERIMENTAL
Intervention: Discrimination experiences
Number of subjects: 139
Study 34229508 — intervention group
Group type: COMPARATOR
Intervention: Control for age, education, race, and intervention condition
Number of subjects: 139
Study 33288629 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose darbepoetin (0.45 µg/kg every 4 weeks)
Number of subjects: 756
Study 33288629 — intervention group
Group type: EXPERIMENTAL
Intervention: Titration-dose darbepoetin (based on hemoglobin levels)
Number of subjects: 756
Study 33288629 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both groups
Number of subjects: 756
Study 32571338 — intervention group
Group type: EXPERIMENTAL
Intervention: Insecticide-treated nets (ITNs)
Number of subjects: 135
Study 34861589 — intervention group
Group type: EXPERIMENTAL
Intervention: Stay Active at Home (SAaH) training program
Number of subjects: 313
Study 34861589 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 313
Study 35175572 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine as adjuvant therapy
Number of subjects: 26
Study 35175572 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment without cimetidine
Number of subjects: 26
Study 33138061 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g/120 kcal whey-protein drink
Number of subjects: 30
Study 33138061 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 g/280 kcal whey-protein drink
Number of subjects: 30
Study 33138061 — intervention group
Group type: COMPARATOR
Intervention: Control (2 kcal) drink
Number of subjects: 30
Study 34292492 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary care (MDC) program for 12 months
Number of subjects: 50
Study 33909293 — intervention group
Group type: EXPERIMENTAL
Intervention: Empowerment-psycho-behavioural programme (13 weeks)
Number of subjects: 250
Study 33909293 — intervention group
Group type: COMPARATOR
Intervention: Health education programme (control group)
Number of subjects: 250
Study 37740217 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D supplementation
Number of subjects: 173
Study 37740217 — intervention group
Group type: COMPARATOR
Intervention: Maintaining sufficient vitamin D levels
Number of subjects: 173
Study 37740217 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study 34697033 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 3234
Study 34697033 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle modification
Number of subjects: 3234
Study 32676977 — intervention group
Group type: COMPARATOR
Intervention: TRV250 (subcutaneous administration)
Number of subjects: 47
Study 32676977 — intervention group
Group type: COMPARATOR
Intervention: TRV250 (oral administration)
Number of subjects: 47
Study 32676977 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oral administration)
Number of subjects: 47
Study 34467598 — intervention group
Group type: EXPERIMENTAL
Intervention: THC + CBD chemovar (9% THC, 10% CBD)
Number of subjects: 159
Study 34467598 — intervention group
Group type: EXPERIMENTAL
Intervention: CBD-dominant chemovar (1% THC, 23% CBD)
Number of subjects: 159
Study 34467598 — intervention group
Group type: COMPARATOR
Intervention: THC-dominant chemovar (24% THC, 1% CBD)
Number of subjects: 159
Study 32033548 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic MRI surgical decision making
Number of subjects: 180
Study 32033548 — intervention group
Group type: COMPARATOR
Intervention: Static MRI surgical decision making
Number of subjects: 180
Study 35472775 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum eye drops (SED)
Number of subjects: 10
Study 35472775 — intervention group
Group type: COMPARATOR
Intervention: Plasma rich in growth factors (PRGF)
Number of subjects: 10
Study 35472775 — intervention group
Group type: COMPARATOR
Intervention: Comparison of SED vs. PRGF
Number of subjects: 10
Study 32971302 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual push technique (MPT)
Number of subjects: 10
Study 33589450 — intervention group
Group type: EXPERIMENTAL
Intervention: TKI plus local consolidative radiation therapy (LCRT)
Number of subjects: 106
Study 33589450 — intervention group
Group type: COMPARATOR
Intervention: TKI alone (standard arm)
Number of subjects: 106
Study 33228592 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycolysis-related six-gene signature (including GOT1, HSPA5, ANGPTL4, PFKM, IER3, PFKFB4)
Number of subjects: 306
Study 33228592 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycolysis-related six-gene signature
Number of subjects: 306
Study 35072414 — intervention group
Group type: EXPERIMENTAL
Intervention: Outside the room ward rounds
Number of subjects: 891
Study 35072414 — intervention group
Group type: COMPARATOR
Intervention: Bedside ward rounds
Number of subjects: 891
Study 32445004 — intervention group
Group type: EXPERIMENTAL
Intervention: Information‐Motivation‐Behavioral skills (IMB) intervention program based on protection motivation theory
Number of subjects: 117
Study 32445004 — intervention group
Group type: COMPARATOR
Intervention: Traditional intervention
Number of subjects: 117
Study 34991348 — intervention group
Group type: EXPERIMENTAL
Intervention: Response-adaptive randomization
Number of subjects: 0
Study 34991348 — intervention group
Group type: EXPERIMENTAL
Intervention: Response-adaptive randomization analysis methods (time-block stratification or re-randomization)
Number of subjects: 0
Study 34991348 — intervention group
Group type: COMPARATOR
Intervention: Fixed 1:1 randomization ratio
Number of subjects: 0
Study 33235123 — intervention group
Group type: EXPERIMENTAL
Intervention: Prewarming group
Number of subjects: 98
Study 33235123 — intervention group
Group type: COMPARATOR
Intervention: Warming group
Number of subjects: 98
Study 33235123 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 98
Study 37552354 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month adjuvant chemotherapy with S-1
Number of subjects: 170
Study 37552354 — intervention group
Group type: COMPARATOR
Intervention: 12-month adjuvant chemotherapy with S-1
Number of subjects: 170
Study 37552354 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month adjuvant chemotherapy with S-1 (in patients who completed the regimen)
Number of subjects: 170
Study 37552354 — intervention group
Group type: COMPARATOR
Intervention: 12-month adjuvant chemotherapy with S-1 (in patients who completed the regimen)
Number of subjects: 170
Study 34339438 — intervention group
Group type: EXPERIMENTAL
Intervention: A‐GPS intervention (quarterly report to clinicians)
Number of subjects: 184
Study 34339438 — intervention group
Group type: COMPARATOR
Intervention: Usual care without A‐GPS (control group)
Number of subjects: 184
Study 34339438 — intervention group
Group type: EXPERIMENTAL
Intervention: A‐GPS intervention
Number of subjects: 184
Study 32799933 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone plus standard intensive care
Number of subjects: 200
Study 32799933 — intervention group
Group type: COMPARATOR
Intervention: Standard intensive care alone
Number of subjects: 200
Study 33994406 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive statin therapy targeting LDL-C <70 mg/dl
Number of subjects: 5042
Study 33994406 — intervention group
Group type: COMPARATOR
Intervention: Standard statin therapy targeting LDL-C 100-120 mg/dl
Number of subjects: 5042
Study 33068371 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% NaCl nasal irrigation
Number of subjects: 80
Study 33068371 — intervention group
Group type: COMPARATOR
Intervention: 0.9% NaCl nasal irrigation
Number of subjects: 80
Study 34891222 — intervention group
Group type: EXPERIMENTAL
Intervention: PPI consultation with people experiencing homelessness aided by Pathway, a UK homeless peer advocacy charity.
Number of subjects: 6
Study 34891222 — intervention group
Group type: EXPERIMENTAL
Intervention: Kolb's Experiential Learning Cycle used for team reflection.
Number of subjects: 6
Study 34256964 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin SR 300 mg once daily for 3 days
Number of subjects: 54
Study 34256964 — intervention group
Group type: COMPARATOR
Intervention: Pregabalin IR 150 mg twice daily for 3 days
Number of subjects: 54
Study 34256964 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin SR 300 mg in fed state
Number of subjects: 54
Study 35182309 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant nivolumab
Number of subjects: 0
Study 35182309 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34097646 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized support at home (monthly home-based visits focusing on nutritional counseling and pregnancy management)
Number of subjects: 617
Study 34097646 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care without personalized support)
Number of subjects: 617
Study 34097646 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized support at home (more than four home visits)
Number of subjects: 617
Study 35609265 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive nomogram incorporating lymphocyte to monocyte ratio (>7.75), neutrophil (>7), AST to ALT ratio (AAR > .86), ALT to lymphocyte ratio index (BLRI > 21.73), alpha‐fetoprotein, and tumor diameter.
Number of subjects: 365
Study 35609265 — intervention group
Group type: EXPERIMENTAL
Intervention: Low probability of VETC group
Number of subjects: 365
Study 34949626 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimised physiotherapist-led treatment package including advice and education, exercise therapy, and orthotics.
Number of subjects: 15
Study 34949626 — intervention group
Group type: EXPERIMENTAL
Intervention: Condition-specific advice, health-promotion advice, exercise types, exercise into 'acceptable' levels of pain, exercise dosage, and type of orthoses.
Number of subjects: 15
Study 34949626 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrotherapy, acupuncture, and manual therapy were excluded from the treatment options.
Number of subjects: 15
Study 35765796 — intervention group
Group type: EXPERIMENTAL
Intervention: Phyto corrective mask (once weekly), phyto corrective gel (twice daily), resveratrol antioxidant serum (at night)
Number of subjects: 10
Study 35765796 — intervention group
Group type: COMPARATOR
Intervention: Intense pulsed light (IPL) treatment
Number of subjects: 10
Study 35765796 — intervention group
Group type: EXPERIMENTAL
Intervention: Both sides treated with sunscreen
Number of subjects: 10
Study 35765796 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient satisfaction questionnaire
Number of subjects: 10
Study 35165099 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib
Number of subjects: 257
Study 35165099 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Number of subjects: 257
Study 35165099 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 257
Study 35165099 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination (Lapatinib and Trastuzumab)
Number of subjects: 257
Study 35165099 — intervention group
Group type: EXPERIMENTAL
Intervention: Ki67% falls ≥50%
Number of subjects: 257
Study 34051120 — intervention group
Group type: EXPERIMENTAL
Intervention: Home Biofeedback Therapy (HBT)
Number of subjects: 30
Study 34051120 — intervention group
Group type: COMPARATOR
Intervention: Office Biofeedback Therapy (OBT)
Number of subjects: 30
Study 32127394 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab + Bevacizumab
Number of subjects: 915
Study 32127394 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 915
Study 35311720 — intervention group
Group type: EXPERIMENTAL
Intervention: Bobath therapy with additional specific soft tissue mobilizations
Number of subjects: 40
Study 35311720 — intervention group
Group type: COMPARATOR
Intervention: Standard Bobath intervention
Number of subjects: 40
Study 33553040 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 g of traditional fermented food (Ash-Kardeh) daily in addition to the usual treatment
Number of subjects: 44
Study 33553040 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment of diabetic patients
Number of subjects: 44
Study 32967500 — intervention group
Group type: EXPERIMENTAL
Intervention: ATP group (androl, thalidomide, and PND capsule)
Number of subjects: 82
Study 32967500 — intervention group
Group type: COMPARATOR
Intervention: AT group (androl and thalidomide)
Number of subjects: 82
Study 34139133 — intervention group
Group type: EXPERIMENTAL
Intervention: Music-based interventions
Number of subjects: 0
Study 34139133 — intervention group
Group type: EXPERIMENTAL
Intervention: Person-centered framework for music interventions
Number of subjects: 0
Study 33866566 — intervention group
Group type: EXPERIMENTAL
Intervention: Iterative Ensemble Smoother (IES)
Number of subjects: 0
Study 33866566 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized Jacobian approach
Number of subjects: 0
Study 33866566 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous increments approach
Number of subjects: 0
Study 33866566 — intervention group
Group type: COMPARATOR
Intervention: Traditional approach using a full Jacobian matrix
Number of subjects: 0
Study 35483677 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 2 μg/kg
Number of subjects: 130
Study 35483677 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine 2.5 μg/kg
Number of subjects: 130
Study 34863115 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise primed tDCS
Number of subjects: 0
Study 34863115 — intervention group
Group type: COMPARATOR
Intervention: Exercise primed sham tDCS
Number of subjects: 0
Study 34863115 — intervention group
Group type: COMPARATOR
Intervention: tDCS alone
Number of subjects: 0
Study 35438672 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g potato protein
Number of subjects: 24
Study 35438672 — intervention group
Group type: COMPARATOR
Intervention: 30 g milk protein
Number of subjects: 24
Study 34839483 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c at 24 to 28 weeks
Number of subjects: 125
Study 34839483 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable or increasing HbA1c during pregnancy
Number of subjects: 125
Study 34839483 — intervention group
Group type: COMPARATOR
Intervention: Decreasing HbA1c during pregnancy
Number of subjects: 125
Study 32895879 — intervention group
Group type: EXPERIMENTAL
Intervention: Person-centred care
Number of subjects: 0
Study 32895879 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 36240954 — intervention group
Group type: EXPERIMENTAL
Intervention: mCT changes at 3 months
Number of subjects: 120
Study 33653909 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Flow Oxygen Therapy (HFT)
Number of subjects: 22
Study 33653909 — intervention group
Group type: COMPARATOR
Intervention: Conventional Oxygen Therapy via T-tube
Number of subjects: 22
Study 35652768 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal analgesia with propofol and sevoflurane (PS)
Number of subjects: 153
Study 35652768 — intervention group
Group type: COMPARATOR
Intervention: Propofol alone (P)
Number of subjects: 153
Study 33356982 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and isoflavone (Ex+Iso, n = 27 females)
Number of subjects: 43
Study 33356982 — intervention group
Group type: COMPARATOR
Intervention: Isoflavone interventions (Iso; n = 16 females)
Number of subjects: 43
Study 32518063 — intervention group
Group type: EXPERIMENTAL
Intervention: Flash glucose monitoring (FGM)
Number of subjects: 100
Study 32518063 — intervention group
Group type: COMPARATOR
Intervention: Conventional self-monitoring of blood glucose (SMBG)
Number of subjects: 100
Study 35818183 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive nursing intervention (nursing support program-based interventions in informational, emotional, and physical dimensions)
Number of subjects: 74
Study 35818183 — intervention group
Group type: COMPARATOR
Intervention: Routine ward care (control group)
Number of subjects: 74
Study 35818183 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive nursing intervention
Number of subjects: 74
Study 34628372 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-Controlled Epidural Analgesia (PCEA)
Number of subjects: 130
Study 34628372 — intervention group
Group type: COMPARATOR
Intervention: Patient-Controlled Intravenous Analgesia (IVPCA)
Number of subjects: 130
Study 32946257 — intervention group
Group type: EXPERIMENTAL
Intervention: HEAR-aware smartphone app tailored to a person's dynamic stage of readiness and acoustical situations.
Number of subjects: 0
Study 32946257 — intervention group
Group type: EXPERIMENTAL
Intervention: HEAR-aware smartphone app
Number of subjects: 0
Study 34910136 — intervention group
Group type: EXPERIMENTAL
Intervention: Anacetrapib 100 mg daily
Number of subjects: 30449
Study 34910136 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 30449
Study 32504204 — intervention group
Group type: EXPERIMENTAL
Intervention: DynaMesh®-IPOM mesh
Number of subjects: 375
Study 32504204 — intervention group
Group type: COMPARATOR
Intervention: Parietex™ Composite mesh
Number of subjects: 375
Study 32504204 — intervention group
Group type: EXPERIMENTAL
Intervention: DynaMesh®-IPOM mesh with mesh surface area ≤ 300 cm2 and same fixation method (Securestrap™)
Number of subjects: 375
Study 32504204 — intervention group
Group type: COMPARATOR
Intervention: Parietex™ Composite mesh with mesh surface area ≤ 300 cm2 and same fixation method (Securestrap™)
Number of subjects: 375